Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLUENASDAQ:CRDFNASDAQ:DSGNNASDAQ:GOSS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUEbluebird bio$4.97$4.55$3.20▼$28.60$48.67M0.27439,137 shsN/ACRDFCardiff Oncology$3.10+2.6%$3.09$2.01▼$5.64$206.24M1.611.19 million shs1.50 million shsDSGNDesign Therapeutics$3.74-1.3%$3.83$2.60▼$7.77$212.32M1.62181,524 shs107,470 shsGOSSGossamer Bio$1.44+11.6%$1.10$0.66▼$1.55$327.31M1.851.44 million shs2.26 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUEbluebird bio0.00%0.00%-0.40%+26.79%-72.36%CRDFCardiff Oncology0.00%-18.64%+2.31%-18.21%+26.53%DSGNDesign Therapeutics0.00%-2.60%-1.84%-24.14%+10.65%GOSSGossamer Bio0.00%+16.13%+20.00%+12.50%+121.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLUEbluebird bio2.5918 of 5 stars3.15.00.00.00.01.71.3CRDFCardiff Oncology1.462 of 5 stars3.50.00.00.02.90.00.6DSGNDesign Therapeutics0.3567 of 5 stars1.01.00.00.00.62.50.6GOSSGossamer Bio3.5273 of 5 stars3.51.00.04.71.51.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUEbluebird bio 2.25Hold$44.60797.38% UpsideCRDFCardiff Oncology 3.00Buy$12.00287.10% UpsideDSGNDesign Therapeutics 2.00Hold$4.006.95% UpsideGOSSGossamer Bio 3.00Buy$7.75438.19% UpsideCurrent Analyst Ratings BreakdownLatest BLUE, CRDF, GOSS, and DSGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025CRDFCardiff OncologyWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/16/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.005/16/2025GOSSGossamer BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.005/9/2025CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.004/17/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.003/31/2025BLUEbluebird bioBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $8.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUEbluebird bio$103.95M0.47N/AN/A$35.59 per share0.14CRDFCardiff Oncology$680K303.30N/AN/A$1.86 per share1.67DSGNDesign TherapeuticsN/AN/AN/AN/A$4.28 per shareN/AGOSSGossamer Bio$114.70M2.85N/AN/A$0.13 per share11.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%8/12/2025 (Estimated)CRDFCardiff Oncology-$45.43M-$0.92N/AN/AN/A-8,308.50%-76.45%-62.85%8/14/2025 (Estimated)DSGNDesign Therapeutics-$49.59M-$0.99N/AN/AN/AN/A-22.85%-22.02%8/4/2025 (Estimated)GOSSGossamer Bio-$56.53M-$0.23N/AN/AN/A-41.12%-128.98%-15.52%8/11/2025 (Estimated)Latest BLUE, CRDF, GOSS, and DSGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GOSSGossamer Bio-$0.18-$0.16+$0.02-$0.16$3.95 million$9.89 million5/14/2025Q1 2025DSGNDesign Therapeutics-$0.28-$0.31-$0.03-$0.31N/AN/A5/8/2025Q1 2025CRDFCardiff Oncology-$0.19-$0.20-$0.01-$0.20$0.09 million$0.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUEbluebird bioN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUEbluebird bio0.370.510.33CRDFCardiff OncologyN/A6.226.22DSGNDesign TherapeuticsN/A28.3728.37GOSSGossamer Bio6.705.715.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUEbluebird bio87.43%CRDFCardiff Oncology16.29%DSGNDesign Therapeutics56.64%GOSSGossamer Bio81.23%Insider OwnershipCompanyInsider OwnershipBLUEbluebird bio1.40%CRDFCardiff Oncology7.70%DSGNDesign Therapeutics31.20%GOSSGossamer Bio6.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableCRDFCardiff Oncology2066.53 million61.40 millionOptionableDSGNDesign Therapeutics4056.77 million39.06 millionOptionableGOSSGossamer Bio180227.30 million212.07 millionOptionableBLUE, CRDF, GOSS, and DSGN HeadlinesRecent News About These CompaniesGossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAHJune 16, 2025 | businesswire.comCantor Fitzgerald Comments on Gossamer Bio FY2026 EarningsJune 10, 2025 | marketbeat.comTwo Sigma Investments LP Raises Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS)June 8, 2025 | marketbeat.comGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | businesswire.comMackenzie Financial Corp Has $271,000 Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS)June 5, 2025 | marketbeat.comTwo Sigma Advisers LP Grows Position in Gossamer Bio, Inc. (NASDAQ:GOSS)June 1, 2025 | marketbeat.comMillennium Management LLC Has $3.24 Million Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS)June 1, 2025 | marketbeat.comHC Wainwright Increases Earnings Estimates for Gossamer BioMay 27, 2025 | marketbeat.comCantor Fitzgerald Comments on Gossamer Bio FY2025 EarningsMay 23, 2025 | marketbeat.comEarnings call transcript: Gossamer Bio exceeds Q1 2025 revenue forecastsMay 17, 2025 | uk.investing.comCantor Fitzgerald maintains Overweight on Gossamer Bio stockMay 17, 2025 | uk.investing.comGOSSAMER BIO Earnings Results: $GOSS Reports Quarterly EarningsMay 17, 2025 | nasdaq.comGossamer Bio, Inc. (NASDAQ:GOSS) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comQ1 2025 Gossamer Bio Inc Earnings CallMay 16, 2025 | finance.yahoo.comGossamer Bio Inc (GOSS) Q1 2025 Earnings Call Highlights: Strategic Progress Amid Financial ...May 16, 2025 | finance.yahoo.comGossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comGossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue EstimatesMay 15, 2025 | zacks.comGossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA StudyMay 15, 2025 | businesswire.comGossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International ConferenceMay 7, 2025 | finance.yahoo.comGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 7, 2025 | businesswire.comGossamer Bio: Initiating Hold As Late‐Stage Data Nears InflectionMay 2, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden Dome3 Top Dividend Stocks Analysts Are Bullish on Right NowBy Chris Markoch | June 6, 2025View 3 Top Dividend Stocks Analysts Are Bullish on Right NowOuster Soars 27% as DoD Grants First 3D LiDAR Approval for DronesBy Leo Miller | June 14, 2025View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones3 Tech Focused ETFs to Watch as the Market Nears All-Time HighsBy Ryan Hasson | June 11, 2025View 3 Tech Focused ETFs to Watch as the Market Nears All-Time HighsDon’t Take Dick’s Sporting Goods Seriously? Big MistakeBy Thomas Hughes | May 29, 2025View Don’t Take Dick’s Sporting Goods Seriously? Big MistakeBLUE, CRDF, GOSS, and DSGN Company Descriptionsbluebird bio NASDAQ:BLUE$4.97 0.00 (0.00%) As of 06/2/2025bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Cardiff Oncology NASDAQ:CRDF$3.10 +0.08 (+2.65%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.10 0.00 (0.00%) As of 06/20/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Design Therapeutics NASDAQ:DSGN$3.74 -0.05 (-1.32%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.74 0.00 (0.00%) As of 06/20/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Gossamer Bio NASDAQ:GOSS$1.44 +0.15 (+11.63%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.43 -0.01 (-0.69%) As of 06/20/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
